Zhang ZM, Yu LF, Li YM, Chen FM, Luo X. Curative effects of peg-interferon α-2a plus ribavirin and ursodeoxycholic acid in chronic hepatitis C patients.
Shijie Huaren Xiaohua Zazhi 2014;
22:1005-1009. [DOI:
10.11569/wcjd.v22.i7.1005]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the curative effects of peg-interferon α-2a plus ribavirin and ursodeoxycholic acid (UDCA) in chronic hepatitis C (CHC) patients.
METHODS: Eighty-four patients with HCV were randomly divided into two groups: an experimental group and a control group. The experiment group was treated by peg-interferon α-2a plus ribavirin and UDCA, and the control group was treated by peg-interferon α-2a plus ribavirin. The response rates in patients with HCV genotype 1 or other genotypes, the improvement of liver function during therapy, autoimmune conditions and interferon side effects were compared.
RESULTS: There was no statistically significant difference between the two groups in the response rates in patients with HCV genotype 1 (9.52% vs 9.52%, 64.29% vs 61.90%, 54.76% vs 54.76%, P > 0.05) or non-genotype 1 (14.29% vs 16.67%, 76.19% vs 73.81%, 76.19% vs 73.81%, P > 0.05). The rates of improvement of ALT at weeks 48 and 72 (80.95% vs 71.43%, 83.33% vs 73.81%, P < 0.05), AST (80.95% vs 64.29%, 85.71% vs 69.05%, 83.33% vs 73.81%, P < 0.05) and GGT at weeks 24, 48 and 72 (85.71% vs 76.19%, 100.00% vs 90.48%, 92.86% vs 80.95%, P < 0.05), and TBIL at weeks 4, 12, 24, 48 and 72 (59.52% vs 47.62%, 76.19% vs 59.52%, 92.86% vs 80.95%, 97.62% vs 83.33%, 92.86% vs 80.95%) were significantly better in the experimental group than in the control group. The positive rate of autoimmune antibody was significantly lower in the experimental group than in the control group (16.67% vs 33.33%, P < 0.05). There were no statistically significant differences in the incidence of hypothyroidism (2.38% vs 4.76%), diabetes (0.00% vs 2.38%), weakness (47.62% vs 47.62%), sore muscle (45.24% vs 47.62%), fever (26.19% vs 28.57%), myelosuppression (23.81% vs 30.95%), or thyroid abnormality (7.14% vs 11.90%).
CONCLUSION: Peg-interferon α-2a plus ribavirin and UDCA can improve the liver function and reduce the side effects of interferon and the occurrence of autoimmune disorder in chronic hepatitis C patients.
Collapse